(Q39034845)

8 September 2017

1 reference

title

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies (English)

1 reference

8 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Cornelia Liedtke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Andrew Tutt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Gunter von Minckwitz

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

6 December 2016

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

10087

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

2430-2442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

Triple-negative breast cancer--current status and future directions

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Triple-negative breast cancer: disease entity or title of convenience?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Response to taxanes in triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Genomic landscape of adenoid cystic carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Classical pathology and mutational load of breast cancer - integration of two worlds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Emerging landscape of oncogenic signatures across human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

An update on PARP inhibitors--moving to the adjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

The AURORA initiative for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Breast cancer stem cells: something out of notching?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Bevacizumab: the phoenix of breast oncology?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932454-0

7 January 2021

10.1016/S0140-6736(16)32454-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27939063%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference